Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib plus temozolomide versus pegylated liposomal doxorubicin in recurrent high grade serous ovarian cancer
2009-015082-31Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- Jan 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer and High-Grade Serous Ovarian Cancer (HGSOC) comparing Veliparib + temozolomide with Pegylated liposomal doxorubicin (2 arms). Primary endpoint: Objective response rate. Started Jan 2010; status: completed.
02
Drugs
veliparibtemozolomidedoxorubicin
03
Conditions
ovarian cancerHigh-Grade Serous Ovarian Cancer (HGSOC)
Beyond the preview
Go deeper on 2009-015082-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015082-31.